ÑAQU MENINGITE
Royuwaay:Drugbox Ñaqu antimeningococcique mooy bépp ñaq bi ñu mëna jëfandikoo ngir mucc ci feebaru Neisseria meningitidis.Amna yeneen xeetu ñaq yu mëna musal nit ki ci yenn ci xeetu meningite yii ñuy lim: A, B, C, W-135, ak Y. Baaxaayu kaaraange ñaqu gi mingi ci diggante 85 ak 100% mën na yàgg gën gaa néew ñaari at. Ci ñi koy jëfandikoo, dina fa wàññi méningite ak sepsie. Ci sidit lañu la koy jam wala ci suufu der bi.
Waa OMS (Mbootaayu sàmm wérgi-yaram ci àdduna bi) waxna ni ñi nekk ci barab yu bari meningite wala yu ko xawa am, dañu wara ñaqu ngir mucci ci feebar bi.[1] Sudee gox yi feebar bi bariwul, nañu ñaq ñi nekk ci wetu ñu am feebar bi.[2] Ci goxu afrique yi nekk ci ndomba meningite, ñu ngi def jéego yu mag ngir ñaq yi am diggante 1 at jàpp 30 at, muy ñaq bi boole ak méningocoque A.[3] Ci Kanada ak ci États-Unis, dañuy digle ñuy faral di ñaq ci saasi bépp xale bu nekk ci barab bi feebar bi nekk te bari fa.[4] Waa Arabi Saudi dañuy sàkku ci képp kuy aji Màkka mu jël ñaq bi koy aar ci meningite.[5]
Ñaqu meningite (Meningococcal), daanaka ñaq bu wóor la.[6] Ci ñénn ñi, barab bi ñu leen ñaq mën na xonk wala mu metti tuuti.[7] Jiggéen ju ëmb mën na ko jëfandikoo.[8] Néew la lool lumuy indi nit ki ay jafe-jafe, matul benn ci 1milioŋi ñaq.[9]
Ci atum 1970 lañu njëkka génne ñaqu meningocoque.[10] Ci limu garab yu am solo yi waa OMS def, mooy ñaq bi gëna am solo bu yaramu nit ki soxla.[11] Ñu ngi jaaye ñaq bi 3,23 ak 10,77 USD dose bu nekk (en gros) li dalee atum 2014.[12] Ci États-Unis, ñu ngi koy jaaye ci diggante 100 ak 200 USD.[13]Royuwaay:TOC limit
- ↑ "Meningococcal A conjugate vaccine: updated guidance, February 2015" (PDF). Wkly. Epidemiol. Rec. 90: 57–62. 20 February 2015. hdl:10665/242320. PMID 25702330.[1]
- ↑ "Meningococcal vaccines: WHO position paper" (PDF). Wkly. Epidemiol. Rec. 86 (47): 521–540. November 2011. hdl:10665/241846. PMID 22128384.[2]
- ↑ "World Health Organization model list of essential medicines: 21st list 2019". World Health Organization. 2019. hdl:10665/325771.
- ↑ "Vaccine, Meningococcal". International Drug Price Indicator Guide. Archived from the original on 10 May 2017. Retrieved 6 December 2015.
- ↑ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 315. ISBN 9781284057560.
- ↑ "22 April 2011 Approval Letter - Menactra". Archived from the original on 28 April 2011. Retrieved 25 April 2011.
- ↑ "1 August 2013 Approval Letter - Menveo". Archived from the original on 28 September 2013. Retrieved 22 September 2013.
- ↑ "Meningococcal Vaccination - What You Should Know". Centers for Disease Control and Prevention (CDC). 26 July 2019. Archived from the original on 20 October 2019. Retrieved 19 October 2019.
- ↑ Reingold AL, Broome CV, Hightower AW, et al. (1985). "Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine". Lancet. 2 (8447): 114–18. doi:10.1016/S0140-6736(85)90224-7. PMID 2862316.
- ↑ Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC (1977). "Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines". Pediatrics. 60 (5): 673–80. PMID 411104.
- ↑ Borrow R, Joseh H, Andrews N, et al. (2000). "Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults". Vaccine. 19 (9–10): 1129–32. doi:10.1016/s0264-410x(00)00317-0. PMID 11137248.
- ↑ MacLennan J, Obaro S, Deeks J, et al. (1999). "Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood". Vaccine. 17 (23–24): 3086–93. doi:10.1016/S0264-410X(99)00139-5. PMID 10462244.
- ↑ Hassan-King MK, Wall RA, Greenwood BM (1988). "Meningococcal carriage, meningococcal disease and vaccination". J Infect. 16 (1): 55–9. doi:10.1016/S0163-4453(88)96117-8. PMID 3130424.